QQ客服 官方微博 反馈留言

	A novel strategy of EGFR-TKI combined chemotherapy in the treatment of human lung cancer with EGFR-sensitive mutation
	Zhang, Lanlin; Qi, Yuan; Xing, Kailin; Qian, Song; Zhang, Ping; Wu, Xianghua
刊名	ONCOLOGY REPORTS
	2018
卷号	40期号:2
关键词	epidermal growth factor receptor tyrosine kinase inhibitor chemotherapy heterogeneity cell cycle lung cancer
ISSN号	1021-335X
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3607831
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Zhang, Lanlin,Qi, Yuan,Xing, Kailin,et al. A novel strategy of EGFR-TKI combined chemotherapy in the treatment of human lung cancer with EGFR-sensitive mutation[J]. ONCOLOGY REPORTS,2018,40(2).
APA	Zhang, Lanlin,Qi, Yuan,Xing, Kailin,Qian, Song,Zhang, Ping,&Wu, Xianghua.(2018).A novel strategy of EGFR-TKI combined chemotherapy in the treatment of human lung cancer with EGFR-sensitive mutation.ONCOLOGY REPORTS,40(2).
MLA	Zhang, Lanlin,et al."A novel strategy of EGFR-TKI combined chemotherapy in the treatment of human lung cancer with EGFR-sensitive mutation".ONCOLOGY REPORTS 40.2(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。